FYERS
Home
/
Stocks
/
Results
/
Astal Laboratories Results

Astal Laboratories Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---289%
---65%
----47%
18%18%18%8%

Peer Comparison

Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
LAURUSLABS-A
ZYDUSLIFE-A
DRREDDY-A
CIPLA-A
MANKIND-A
AUROPHARMA-A
LUPIN-A
ASTALLTD-X
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,788.9₹425150 Cr38.778.2958.23₹11479 Cr
9,981.5₹266265 Cr91.0334.04128.41₹2568 Cr
4,640₹176301 Cr8314.04106.21₹2163 Cr
2,319.4₹125352 Cr93.568.1733.94₹889 Cr
1,260₹123591 Cr27.399.4262.53₹5040 Cr
1,374.5₹114351 Cr40.8411.0859.2₹4196 Cr
1,395.9₹112474 Cr38.8210.8652.6₹3879 Cr
2,486₹102315 Cr45.6217.2376.26₹1913 Cr
1,701.6₹97757 Cr26.3317.9596.84₹3505 Cr
2,020.5₹92007 Cr16.6430.95154.35₹5333 Cr
54.55₹224 Cr15.262.153.64₹15 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Mar 2025
₹101 Cr₹134 Cr₹23 Cr
₹14 L₹10 L₹4 L
₹101 Cr₹134 Cr₹24 Cr
₹90 Cr₹125 Cr₹19 Cr
₹12 Cr₹10 Cr₹4 Cr
₹1 Cr₹1 Cr₹27 L
₹10 Cr₹8 Cr₹4 Cr
₹9 Cr₹8 Cr₹3 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025
——
₹42 Cr₹10 Cr
₹2 Cr₹4 Cr
₹289 Cr₹22 Cr
₹289 Cr₹22 Cr
₹334 Cr₹36 Cr
₹19 Cr₹46 L
₹86 L₹12 L
₹65 L₹0
₹20 Cr₹57 L
——
₹124 Cr₹11 Cr
₹11 Cr₹3 Cr
₹30 Cr₹13 Cr
₹165 Cr₹27 Cr
₹519 Cr₹63 Cr
₹49 Cr₹13 Cr
——
₹70 Cr₹16 Cr
₹5 Cr₹4 Cr
₹64 Cr₹11 Cr
₹203 Cr₹0
₹203 Cr₹0
₹4 Cr₹4 Cr
₹3 Cr₹2 Cr
₹276 Cr₹18 Cr
——
₹68 Cr₹15 Cr
₹157 Cr₹28 Cr
₹70 L₹2 Cr
₹18 Cr₹1 Cr
₹243 Cr₹46 Cr
₹78 Cr₹19 Cr
₹519 Cr₹63 Cr
₹79₹33
₹79₹33

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025
₹18 Cr₹12 Cr
₹3 Cr₹80 L
-₹37 Cr-₹25 Cr
-₹17 Cr-₹12 Cr
-₹18 Cr-₹13 Cr
-₹2 Cr-₹8 Cr
₹3 Cr₹3 Cr
-₹17 Cr-₹17 Cr
-₹11 Cr₹6 Cr
-₹28 Cr-₹11 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)51.85
Volume (₹)9,333.00
High (₹)54.55
Upper Circuit61.50
Low (₹)51.00
Lower Circuit41.00
Prev Close51.25
52W High (₹)99.90
Price54.55
52W Low (₹)49.99

Share Market Cap & Key Ratios Overview

M.Cap (₹)224.47 Cr
Div. Yield (%)0.00
PE Ratio15.26
Debt to Equity0.15
Price to Book0.83
Book Value78.57
EPS (TTM)3.36
Face Value10.00
ROE (%)8.08

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
LAURUSLABS-ANSE
ZYDUSLIFE-ANSE
DRREDDY-ANSE
CIPLA-ANSE
MANKIND-ANSE
AUROPHARMA-ANSE
LUPIN-ANSE
ASTALLTD-XNSE
LTP
1W Low
1W High
Market cap (₹)
1788.9+10.65 (0.60%)
1720.80
1796.45
4,25,150Cr
9981.5+266.5 (2.74%)
9866.35
10080.20
2,66,265Cr
4640+4.85 (0.10%)
4555
4665.10
1,76,301Cr
2319.4-72.6 (-3.04%)
2252.50
2442
1,25,352Cr
1260+16 (1.29%)
1217.70
1264.20
1,23,591Cr
1374.5+24.3 (1.80%)
1337.30
1390.70
1,14,351Cr
1395.9+15.9 (1.15%)
1364.75
1400.60
1,12,474Cr
2486-2.75 (-0.11%)
2457.35
2523.70
1,02,315Cr
1701.6+23.8 (1.42%)
1656.90
1707.60
97,757Cr
2020.5+11.5 (0.57%)
1989.10
2061.55
92,007Cr
54.55-7.15 (-11.59%)
49.99
62.90
224Cr

Astal Laboratories Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹12.39Cr; with other income of ₹13.8Lakh, profit before interest and tax came to ₹11.53Cr. Interest expense was ₹1.18Cr; PBT before exceptional items stood at ₹10.35Cr. Cost mix (full year): raw materials ₹62.36Cr; employee cost ₹1.26Cr; depreciation ₹86Lakh; other expenses ₹88.69Cr. Basis: consolidated annual results.

Astal Laboratories Ltd Quaterly Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹12.39Cr; with other income of ₹13.8Lakh, profit before interest and tax came to ₹11.53Cr. Interest expense was ₹1.18Cr, taking profit before tax to ₹10.35Cr.